Stockscreener 앱 받기
1.61
1.90%
0.03
시간 외 거래:
1.56
-0.05
-3.11%
전일 마감가:
$1.58
열려 있는:
$1.57
하루 거래량:
897.24K
Relative Volume:
0.44
시가총액:
$241.32M
수익:
$42.17M
순이익/손실:
$-183.12M
주가수익비율:
-1.1056
EPS:
-1.4562
순현금흐름:
$-138.51M
1주 성능:
-4.73%
1개월 성능:
-5.85%
6개월 성능:
+0.00%
1년 성능:
+77.45%
1일 변동 폭
$1.5401
$1.625
1주일 범위
$1.5401
$1.76
52주 변동 폭
$0.71
$2.6158
Coherus Oncology Inc Stock (CHRS) Company Profile
명칭
Coherus Oncology Inc
전화
(650) 649-3530
주소
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
Compare CHRS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CHRS
Coherus Oncology Inc
|
1.61 | 236.83M | 42.17M | -183.12M | -138.51M | -1.4562 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-23 | 개시 | Oppenheimer | Outperform |
| 2025-09-04 | 업그레이드 | Maxim Group | Hold → Buy |
| 2024-08-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-11-17 | 개시 | Robert W. Baird | Outperform |
| 2023-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2023-07-24 | 개시 | Citigroup | Buy |
| 2023-05-01 | 개시 | Truist | Buy |
| 2023-03-28 | 업그레이드 | UBS | Neutral → Buy |
| 2022-06-14 | 개시 | UBS | Neutral |
| 2022-03-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-07-16 | 개시 | BofA Securities | Neutral |
| 2020-04-17 | 개시 | SunTrust | Buy |
| 2019-08-13 | 개시 | Mizuho | Buy |
| 2019-08-02 | 재확인 | H.C. Wainwright | Buy |
| 2019-08-02 | 재확인 | Maxim Group | Buy |
| 2019-06-11 | 개시 | Barclays | Overweight |
| 2019-05-07 | 개시 | H.C. Wainwright | Buy |
| 2018-08-28 | 개시 | H.C. Wainwright | Buy |
| 2018-03-09 | 재확인 | Maxim Group | Buy |
| 2017-08-08 | 재확인 | JP Morgan | Overweight |
| 2017-06-13 | 재확인 | Maxim Group | Buy |
| 2017-05-05 | 개시 | BMO Capital Markets | Outperform |
| 2016-10-19 | 개시 | Robert W. Baird | Outperform |
| 2016-09-07 | 개시 | Maxim Group | Buy |
| 2016-07-27 | 개시 | Citigroup | Buy |
| 2016-01-20 | 개시 | Credit Suisse | Outperform |
모두보기
Coherus Oncology Inc 주식(CHRS)의 최신 뉴스
Coherus Oncology announces proposed public offering of common stock - MSN
CHRS Technical Analysis & Stock Price Forecast - Intellectia AI
Coherus BioSciences Q4 2025 earnings preview - MSN
Coherus Oncology (CHRS) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
Coherus Oncology Pivots to Immuno-Oncology, Touts LOQTORZI Growth and New Pipeline at Citizens Conf. - MarketBeat
Coherus Oncology (NASDAQ:CHRS) Upgraded at Wall Street Zen - MarketBeat
Coherus Oncology, Inc. (NASDAQ:CHRS) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Coherus Oncology (CHRS) price target increased by 13.33% to 5.78 - MSN
Coherus Oncology (CHRS) Revenue Gains Contrast With Persistent US$46 Million Quarterly Losses - Sahm
Coherus outlines $175M annualized LOQTORZI target by 2028 as commercial expansion accelerates - MSN
Coherus BioSciences at The Citizens Conference: Strategic Oncology Shift By Investing.com - Investing.com Canada
CHRS: Rapid oncology pipeline progress and strong LOQTORZI sales drive growth and pivotal trial plans - TradingView
Coherus Oncology Doubles LOQTORZI Revenue in 2025, Advances Oncology Pipeline and Significantly Reduces Debt 1 - Minichart
Oppenheimer reiterates Coherus Biosciences stock rating at Outperform By Investing.com - Investing.com India
Oppenheimer reiterates Coherus Biosciences stock rating at Outperform - Investing.com
Coherus Oncology, Inc. 2025 Annual Report – LOQTORZI Sales Growth, Pipeline Advances, and Strategic Shift to Immuno-Oncology - Minichart
Coherus Oncology Inc (CHRS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Coherus Oncology Q4 2025 Earnings Call Transcript - MarketBeat
Coherus Oncology Inc (CHRS) Q4 2025 Earnings Call Highlights: St - GuruFocus
Coherus Oncology (CHRS) Sees Strong Growth with LOQTORZI - GuruFocus
Coherus Oncology Reports Q4 Earnings Loss - National Today
Coherus Oncology Q4 Earnings Call Highlights - MarketBeat
CHRS: LOQTORZI sales doubled, debt slashed, and key oncology trials advance toward 2026 data - TradingView
CHRS: LOQTORZI revenue doubled, debt slashed, and pipeline advances set up major 2026 milestones - TradingView
CHRS Q4 Revenue Falls Short but Strategic Shift Shows Promise - GuruFocus
Coherus Oncology Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Coherus Oncology (CHRS) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Coherus Oncology Q4 2025 Results: Quarterly Loss, Annual ProfitNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Coherus Oncology: Fourth Quarter Financial Results Overview - Bitget
Coherus Oncology (NASDAQ:CHRS) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Coherus Oncology (NASDAQ: CHRS) reports 2025 results and sharp debt cut - Stock Titan
Coherus Oncology: Q4 Earnings Snapshot - Barchart.com
Coherus Oncology Q4 revenue misses estimates - TradingView
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update - The Manila Times
BRIEF-Coherus Oncology Q4 Sales USD 12.748 Million Vs. IBES Estimate USD 13.9 Million - TradingView
Cancer drug LOQTORZI sales double to $40.8M as trials near - Stock Titan
Coherus BioSciences (CHRS) Q4 Earnings Preview: What to Expect - GuruFocus
Coherus Oncology Touts 90% Debt Cut, LOQTORZI Sales Surge, Sets 2026 Data Catalysts - National Today
Coherus Oncology Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Coherus BioSciences's Earnings Outlook - Benzinga
How The Coherus Oncology (CHRS) Narrative Is Evolving Around Clinical Catalysts And Valuation Risks - Yahoo Finance
Coherus BioSciences at TD Cowen Conference: Strategic Oncology Shift - Investing.com
CHRS: Strong oncology focus, robust pipeline, and accelerating LOQTORZI sales drive future growth - TradingView
CHRS: Rapid oncology transformation, strong LOQTORZI growth, and promising pipeline assets drive outlook - TradingView
Coherus Oncology, Inc. to Release 2025 Financial Results on March 9, 2026, with Conference Call to Follow - Quiver Quantitative
Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026 - GlobeNewswire
Coherus Oncology (CHRS) Projected to Post Quarterly Earnings on Monday - MarketBeat
CHRS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Phathom Pharmaceuticals, Inc. (PHAT) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
CHRS PE Ratio & Valuation, Is CHRS Overvalued - Intellectia AI
Hepatocellular Carcinoma Clinical Trial Pipeline Shows Potential with Active Contributions from 90+ Key Companies | DelveInsight - StreetInsider
Coherus Oncology Inc (CHRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):